Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Boehringer Ingelheim
Dow
Johnson and Johnson
Mallinckrodt

Last Updated: January 18, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for FG-3019


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug FG-3019?

FG-3019 is an investigational drug.

There have been 18 clinical trials for FG-3019. The most recent clinical trial was a Phase 2 trial, which was initiated on July 30th 2020.

The most common disease conditions in clinical trials are Fibrosis, Pulmonary Fibrosis, and Idiopathic Pulmonary Fibrosis. The leading clinical trial sponsors are FibroGen, Jonsson Comprehensive Cancer Center, and [disabled in preview].

There are fourteen US patents protecting this investigational drug and ninety-three international patents.

Recent Clinical Trials for FG-3019
TitleSponsorPhase
A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids, in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)FibroGenPhase 3
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)FibroGenPhase 3
A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)FibroGenPhase 3

See all FG-3019 clinical trials

Clinical Trial Summary for FG-3019

Top disease conditions for FG-3019
Top clinical trial sponsors for FG-3019

See all FG-3019 clinical trials

US Patents for FG-3019

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
FG-3019 ⤷  Sign up for a Free Trial Aerosol pirfenidone and pyridone analog compounds and uses thereof Avalyn Pharma Inc. (Seattle, WA) ⤷  Sign up for a Free Trial
FG-3019 ⤷  Sign up for a Free Trial Method of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA) ⤷  Sign up for a Free Trial
FG-3019 ⤷  Sign up for a Free Trial Inhibitors of endoglin activity for the treatment of fibrosis Tufts Medical Center, Inc. (Boston, MA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for FG-3019

Drugname Country Document Number Estimated Expiration Related US Patent
FG-3019 Australia AU2012212269 2031-01-31 ⤷  Sign up for a Free Trial
FG-3019 Australia AU2013207409 2031-01-31 ⤷  Sign up for a Free Trial
FG-3019 Australia AU2013295800 2031-01-31 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Boehringer Ingelheim
Dow
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.